BP-897

BP-897
Clinical data
ATC code
  • none
Identifiers
IUPAC name
  • N-[4-[4-(2-methoxyphenyl)piperazin-1-yl]butyl]naphthalene-2-carboxamide
CAS Number
PubChem CID
IUPHAR/BPS
ChemSpider
UNII
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.150.041
Edit this at Wikidata
Chemical and physical data
FormulaC26H31N3O2
Molar mass417.553 g·mol−1
3D model (JSmol)
SMILES
  • COc1ccccc1N3CCN(CC3)CCCCNC(=O)c4ccc2ccccc2c4
InChI
  • InChI=1S/C26H31N3O2/c1-31-25-11-5-4-10-24(25)29-18-16-28(17-19-29)15-7-6-14-27-26(30)23-13-12-21-8-2-3-9-22(21)20-23/h2-5,8-13,20H,6-7,14-19H2,1H3,(H,27,30) ☒N
  • Key:MNHDKMDLOJSCGN-UHFFFAOYSA-N ☒N
 ☒NcheckY (what is this?)  (verify)

BP-897 is a drug used in scientific research which acts as a moderately selective dopamine D3 receptor partial agonist.[1] It has mainly been used in the study of treatments for cocaine addiction.[2][3][4][5][6][7][8]

References

  1. ↑ Pilla M, Perachon S, Sautel F, Garrido F, Mann A, Wermuth CG, Schwartz JC, Everitt BJ, Sokoloff P (July 1999). "Selective inhibition of cocaine-seeking behaviour by a partial dopamine D3 receptor agonist". Nature. 400 (6742): 371–5. doi:10.1038/22560. PMID 10432116. S2CID 4351316.
  2. ↑ Beardsley PM, Sokoloff P, Balster RL, Schwartz JC (February 2001). "The D3R partial agonist, BP 897, attenuates the discriminative stimulus effects of cocaine and D-amphetamine and is not self-administered". Behavioural Pharmacology. 12 (1): 1–11. doi:10.1097/00008877-200102000-00001. PMID 11270507. S2CID 25443354.
  3. ↑ Garcia-Ladona FJ, Cox BF (2003). "BP 897, a selective dopamine D3 receptor ligand with therapeutic potential for the treatment of cocaine-addiction". CNS Drug Reviews. 9 (2): 141–58. doi:10.1111/j.1527-3458.2003.tb00246.x. PMC 6741652. PMID 12847556.
  4. ↑ Duarte C, Lefebvre C, Chaperon F, Hamon M, Thiébot MH (November 2003). "Effects of a dopamine D3 receptor ligand, BP 897, on acquisition and expression of food-, morphine-, and cocaine-induced conditioned place preference, and food-seeking behavior in rats". Neuropsychopharmacology. 28 (11): 1903–15. doi:10.1038/sj.npp.1300276. PMID 12915863.
  5. ↑ Hsu A, Togasaki DM, Bezard E, Sokoloff P, Langston JW, Di Monte DA, Quik M (November 2004). "Effect of the D3 dopamine receptor partial agonist BP897 [N-[4-(4-(2-methoxyphenyl)piperazinyl)butyl]-2-naphthamide] on L-3,4-dihydroxyphenylalanine-induced dyskinesias and parkinsonism in squirrel monkeys". The Journal of Pharmacology and Experimental Therapeutics. 311 (2): 770–7. doi:10.1124/jpet.104.071142. PMID 15226382. S2CID 15481124.
  6. ↑ Gilbert JG, Newman AH, Gardner EL, Ashby CR, Heidbreder CA, Pak AC, Peng XQ, Xi ZX (July 2005). "Acute administration of SB-277011A, NGB 2904, or BP 897 inhibits cocaine cue-induced reinstatement of drug-seeking behavior in rats: role of dopamine D3 receptors". Synapse (New York, N.Y.). 57 (1): 17–28. doi:10.1002/syn.20152. PMC 3726034. PMID 15858839.
  7. ↑ Spiller K, Xi ZX, Peng XQ, Newman AH, Ashby CR, Heidbreder C, Gaál J, Gardner EL (March 2008). "The selective dopamine D3 receptor antagonists SB-277011A and NGB 2904 and the putative partial D3 receptor agonist BP-897 attenuate methamphetamine-enhanced brain stimulation reward in rats". Psychopharmacology. 196 (4): 533–42. doi:10.1007/s00213-007-0986-6. PMC 3713235. PMID 17985117.
  8. ↑ Hocke C, Prante O, Salama I, Hübner H, Löber S, Kuwert T, Gmeiner P (May 2008). "18F-Labeled FAUC 346 and BP 897 derivatives as subtype-selective potential PET radioligands for the dopamine D3 receptor". ChemMedChem. 3 (5): 788–93. doi:10.1002/cmdc.200700327. PMID 18306190. S2CID 23143152.


This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.